Literature DB >> 8155649

Analysis of the binding of 3,3',5-triiodo-L-thyronine and its analogues to mutant human beta 1 thyroid hormone receptors: a model of the hormone binding site.

S Y Cheng1, S C Ransom, P McPhie, M K Bhat, A J Mixson, B D Wintraub.   

Abstract

To understand the nature of the thyroid hormone binding site, we characterized the binding of 3,3',5-triiodo-L-thyronine (T3) and its analogues to eight naturally occurring mutated human beta 1 thyroid hormone receptors (h-TR beta 1). The mutant receptors were derived from patients with the syndrome of generalized thyroid hormone resistance, and each has a point mutation in the hormone binding domain (KT, R338W; TP, L450H; IR, D322H; NN, G347E; AH, P453H; OK, M442V; RL, F459C; and ED, A317T). Compared to the wild-type h-TR beta 1, binding of T3 was reduced by as much as 97% for the mutants. The order of binding affinity of wild-type h-TR beta 1 to the analogues is T3 > D-T3 > L-thyroxine > 3,5-diiodo-L-thyronine > 3,3',5'-triiodo-L-thyronine. The mutant receptors showed essentially the same order of reduced affinities for the analogues, but the amounts of the reductions varied in each case. These results suggest specific local interactions (interplay) of analogues with the mutated residues in the receptors. On the basis of these data and a putative structure of the hormone binding domains as an eight-stranded alpha/beta barrel, we propose the location of the hormone in the binding site of h-TR beta 1. Ionic bonds anchor the hormone's alanine side chain to loop 4 of the 8-fold alpha/beta barrel. The phenyl ring lies across the amino-terminal face of the domain with the phenoxy ring pointing downward into the barrel interacting with beta-strand 8 on the opposite side.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8155649     DOI: 10.1021/bi00180a028

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor.

Authors:  A Quamrul Hassan; John T Koh
Journal:  J Am Chem Soc       Date:  2006-07-12       Impact factor: 15.419

Review 2.  Mutational Landscape of Resistance to Thyroid Hormone Beta (RTHβ).

Authors:  Paola Concolino; Alessandra Costella; Rosa Maria Paragliola
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

3.  The N-terminal portion of domain E of retinoic acid receptors alpha and beta is essential for the recognition of retinoic acid and various analogs.

Authors:  J Ostrowski; L Hammer; T Roalsvig; K Pokornowski; P R Reczek
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

4.  3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice.

Authors:  Wenke Jonas; Julika Lietzow; Franziska Wohlgemuth; Carolin S Hoefig; Petra Wiedmer; Ulrich Schweizer; Josef Köhrle; Annette Schürmann
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

Review 5.  Tissue thyroid hormones and thyronamines.

Authors:  Alice Accorroni; Federica Saponaro; Riccardo Zucchi
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

Review 6.  Screening methods for thyroid hormone disruptors.

Authors:  M DeVito; L Biegel; A Brouwer; S Brown; F Brucker-Davis; A O Cheek; R Christensen; T Colborn; P Cooke; J Crissman; K Crofton; D Doerge; E Gray; P Hauser; P Hurley; M Kohn; J Lazar; S McMaster; M McClain; E McConnell; C Meier; R Miller; J Tietge; R Tyl
Journal:  Environ Health Perspect       Date:  1999-05       Impact factor: 9.031

Review 7.  Thyroid hormone resistance syndrome caused by heterozygous A317T mutation in thyroid hormone receptor β gene: Report of one Chinese pedigree and review of the literature.

Authors:  Qing-Hua Guo; Bao-An Wang; Chen-Zhi Wang; Min Wang; Ju-Ming Lu; Zhao-Hui Lv; Yi-Ming Mu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.